Judge Questions Hegseth's Testosterone Policy for Older Soldiers 2026

The testosterone policy introduced by Defense Secretary Pete Hegseth for older soldiers is now under judicial scrutiny. A federal judge has ordered the Trump administration to explain discrepancies between this policy and the treatment of transgender troops. The policy aims to screen male service members aged 30 and older for low testosterone levels and offer replacement therapy to boost combat readiness.

New Testosterone Screening for Older Soldiers

Hegseth announced the initiative earlier this month, stating that checking testosterone levels will keep soldiers on the “leading edge of lethality.” The program, dubbed the “High-T department of war,” allows volunteers with low testosterone to undergo testosterone replacement therapy (TRT). Supporters argue it enhances performance, but critics question the medical and ethical implications.

Judge Questions Discrepancy with Transgender Troops

On Wednesday, Judge Ana Reyes of the District of Columbia district court highlighted a contradiction: the Pentagon promotes TRT for cisgender soldiers while using the need for hormone treatment as a reason to ban transgender troops. In her order, she cited Trump’s executive order that bars transgender individuals from serving unless they meet standards “without the benefit of routine medical treatment.” The judge demanded the Pentagon explain the basis for this different treatment.

Key Takeaways from the Legal Challenge

• Federal judge orders the Pentagon to clarify the rationale behind treating hormone therapy differently for older soldiers vs. transgender service members.
• The Trump administration’s ban on transgender troops faces two lawsuits, with this latest order adding pressure.
• Cost and administration of TRT for older soldiers are also being questioned in the judge’s request.

This case underscores ongoing tensions between military readiness policies and equal treatment under the law. As the Pentagon drafts its response, observers await clarity on whether hormone therapy is a health tool or a disqualifying condition.

FAQ